Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ziprasidone Mesylate

FDA-approved product (powder, intramuscular), marketed as Geodon, Ziprasidone Hydrochloride, Ziprasidone Mesylate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ziprasidone Mesylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Agitation
  • Bipolar disorder
  • Bipolar I disorder
  • Cardiac arrhythmia
  • Psychosis
  • Schizoaffective disorder
  • Schizophrenia
  • Ventricular tachycardia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Indole derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli50.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis52.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ziprasidone Mesylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ziprasidone Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • The CAMPUS Project: Cholinergic Augmentation of Cognitive Deficits in Schizophrenia

    NCT00206947 · start 2002-12

    Registered record
    Registry ID
    NCT00206947
    Conditions
    Schizophrenia
    Interventions
    donepezil (5-10 mg/day); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2002-12
    Completion
    2005-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventiondonepezil (5-10 mg/day); Placebo
    PhasePhase 2
    Registry statusTerminated

  • Ziprasidone in Early Onset Schizophrenia Spectrum Disorders

    NCT01006551 · start 2002-12

    Registered record
    Registry ID
    NCT01006551
    Conditions
    Schizophrenia
    Interventions
    Ziprasidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-12
    Completion
    2006-02
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionZiprasidone
    PhasePhase 2
    Registry statusCompleted

  • Ziprasidone in Children With Autism: A Pilot Study

    NCT00208559 · start 2002-02

    Registered record
    Registry ID
    NCT00208559
    Conditions
    Autism
    Interventions
    Ziprasidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-02
    Completion
    2006-08
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutism
    InterventionZiprasidone
    PhasePhase 2
    Registry statusCompleted

  • Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)

    NCT00418171 · start 2002-02

    Registered record
    Registry ID
    NCT00418171
    Conditions
    Schizophrenia
    Interventions
    Ziprasidone; Olanzapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-02
    Completion
    2007-04
    Enrolment
    18,239

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionZiprasidone; Olanzapine
    PhasePhase 4
    Registry statusCompleted

  • CATIE- Schizophrenia Trial

    NCT00014001 · start 2000-12

    Registered record
    Registry ID
    NCT00014001
    Conditions
    Schizophrenia
    Interventions
    perphenazine; olanzapine; quetiapine; risperidone; ziprasidone; clozapine; fluphenazine decanoate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2000-12
    Completion
    2004-12
    Enrolment
    1,600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionperphenazine; olanzapine; quetiapine; risperidone +3 more
    PhasePhase 4
    Registry statusCompleted